Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTff Pharmaceuticals Inc

Tff Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2025-03-26T07:54:29.018554Z
Market Cap
6.85M

Momentum Score

…

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
1.54
Low
15.95
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
-
Dividend Yield
-
Revenue TTM
0.73M
Revenue Per Share
0.41
Gross Profit TTM
-21.21M
Debt / Equity
0.01
ROE
-130.94%
Net Debt
-5.36M
ROCE
-331.26%
Diluted EPS TTM
-9.38

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -31.77M -31.04M -18.57M -11.87M -3.84M
Minority interest - 31.04M - - -
Net income -31.77M -30.99M -18.44M -11.75M -3.84M
Selling general administrative 13.80M 10.57M 8.01M 3.17M 3.05M
Gross profit - 0.00M - - -
Reconciled depreciation 0.39M 0.11M - - -
Ebit -31.80M -31.79M -18.57M -11.87M -3.90M
Ebitda -31.41M -31.68M -18.69M -11.99M -
Depreciation and amortization 0.39M 0.11M - - -
Non operating income net other - 0.70M - - -
Operating income -31.80M -31.79M -18.69M -11.99M -3.90M
Other operating expenses 31.80M 31.79M 18.69M 11.99M -
Interest expense -0.03M 0.75M 0.00M 0.00M 0.00M
Interest income 0.03M 0.05M 0.13M 0.12M 0.06M
Net interest income 0.03M 0.05M 0.13M 0.12M -
Income tax expense -0.00M -0.05M -0.13M -0.12M -
Total revenue 0.00M 0.00M 0.00M 0.00M -
Total operating expenses 31.80M 31.79M 18.69M 11.99M 3.90M
Total other income expense net 0.03M 0.75M 0.13M 0.12M 0.06M
Net income from continuing ops -31.77M -31.04M -18.57M -11.87M -3.84M
Net income applicable to common shares - -31.04M -18.57M -36.68M -4.57M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 12.03M 24.12M 40.70M 38.66M 29.19M
Other current assets 1.68M 2.23M 2.45M 2.26M 1.09M
Total liab 2.46M 1.24M 1.96M 1.32M 1.54M
Total stockholder equity 9.57M 22.88M 38.74M 37.34M 27.64M
Other current liab 1.29M 0.00M 0.42M 0.02M -
Common stock 0.00M 0.04M 0.03M 0.02M 0.02M
Capital stock 0.00M 0.04M 0.03M 0.02M 0.02M
Retained earnings -118.33M -97.09M -65.32M -34.28M -15.71M
Other liab - - - - 1.13M
Cash 5.48M 16.61M 33.79M 35.30M 28.09M
Total current liabilities 2.43M 1.13M 1.96M 1.32M 0.41M
Current deferred revenue 0.10M 0.13M 0.05M 0.02M -
Net debt -5.36M -16.42M -33.79M -35.30M -28.09M
Short term debt 0.08M 0.08M - - -
Short long term debt total 0.12M 0.19M - - -
Other stockholder equity 128.04M 120.07M 104.08M 71.65M 43.34M
Property plant equipment - - 1.86M 1.10M -
Total current assets 7.59M 19.03M 38.84M 37.56M 29.19M
Net tangible assets - - 38.74M 37.34M 27.64M
Net receivables 0.43M 0.19M 2.60M - -
Accounts payable 0.96M 0.92M 1.49M 1.30M 0.41M
Accumulated other comprehensive income -0.15M -0.14M -0.05M -0.05M -29.19M
Common stock total equity - - 0.03M 0.02M 0.02M
Retained earnings total equity - - -65.32M -34.28M -
Non currrent assets other 2.32M 1.82M - - 0.00M
Non current assets total 4.44M 5.10M 1.86M 1.10M 0.00M
Capital lease obligations 0.12M 0.19M - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -1.55M -0.87M -1.10M 0.00M -
Change to liabilities - 0.23M 0.86M 0.01M 0.40M
Total cashflows from investing activities - -0.87M -1.10M -1.10M -1.10M
Total cash from financing activities 11.75M 28.88M 24.99M 29.05M 12.39M
Change to operating activities - -2.41M -1.12M 0.05M -0.01M
Net income -31.77M -31.04M -18.57M -11.87M -3.84M
Change in cash -17.18M -1.51M 7.21M 17.83M 10.26M
Begin period cash flow 33.79M 35.30M 28.09M 10.26M -
End period cash flow 16.61M 33.79M 35.30M 28.09M 10.26M
Total cash from operating activities -27.34M -29.56M -16.62M -11.22M -2.13M
Issuance of capital stock 0.40M 28.02M 24.28M 29.05M -
Depreciation 0.39M 0.11M 0.11M 0.11M 0.11M
Dividends paid - - - -0.88M -
Sale purchase of stock - 0.18M - 29.05M 12.49M
Other cashflows from financing activities 11.35M 0.87M 0.71M 8.07M -0.10M
Change to netincome - 3.55M 2.19M 0.59M 1.33M
Capital expenditures 1.55M 0.87M 1.10M 1.10M 1.10M
Cash flows other operating - -2.80M -1.10M - -
Cash and cash equivalents changes - -1.54M 7.28M - -
Change in working capital -0.21M -2.18M -0.24M 0.06M -
Stock based compensation 4.25M 3.55M 2.19M 0.59M -
Other non cash items - -31.01M -7.70M -19.60M -
Free cash flow -28.89M -30.43M -17.72M -11.22M -

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 0.01
0.02%		 40.31 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Tff Pharmaceuticals Inc

TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions. The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection. It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines. It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs. TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.

1751 River Run, Fort Worth, TX, United States, 76107

817 438 6168

https://tffpharma.com

19

Name Title Year Born
Dr. Harlan F. Weisman Interim CEO & Vice Chairman 1952
Mr. Kirk Allen Coleman CFO, Treasurer & Sec. 1974
Mr. Christopher Cano COO & VP of Bus. Devel. 1971
Dr. Anthony J. Hickey Ph.D. Chief Scientific Officer NA
Dr. Dale Christensen Ph.D. Head of Clinical Devel. NA
Mr. Paul F. Manley Head of Regulatory Affairs NA
Dr. Harlan F. Weisman President, CEO & Director 1952
Mr. Kirk Allen Coleman CFO, Treasurer & Secretary 1974
Dr. Zamaneh Mikhak M.D. Chief Medical Officer 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

ITH
CAD 2.15
+27.68%
HG
CAD 4.11
+19.13%
PPTA
CAD 27.74
+17.99%
UCU
CAD 2.10
+17.32%
GAU
CAD 3.49
+16.72%
TSU
CAD 29.67
-29.71%
PXT
CAD 19.73
-16.91%
LAS-A
CAD 230.50
-9.25%
IFP
CAD 13.50
-8.35%
NFI
CAD 24.01
-7.80%

Equity Sectors*

  • Basic Materials

    +3.74%

  • Communication Services

    +0.56%

  • Consumer Cyclical

    -0.34%

  • Consumer Defensive

    +0.11%

  • Energy

    +1.33%

  • Financial Services

    -0.26%

  • Healthcare

    +2.54%

  • Industrials

    -0.11%

  • Real Estate

    -0.23%

  • Technology

    +1.91%

  • Utilities

    +1.05%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…